Authoritative biopharmaceutical intelligence — patents, pipelines, litigation, pricing, and global market opportunities — at your fingertips.
Stop waiting for analyst reports. Access primary source data — updated continuously — across every dimension of the pharmaceutical market.
People switch to DrugPatentWatch because they're tired of the high cost and low quality of their analysts. You shouldn't have to wait for a report to understand your market.
Every drug is perpetually updatd from primary sources. The latest information is always available — no delays, no filters, no spin.
Analysts aren't oracles. They're people working with the same public data you could access yourself — just a few weeks later, after three rounds of internal review, dressed up in a 60-page PDF with a lot of confident language.
The data doesn't get better in the meantime. A patent expiry date is a patent expiry date. The FDA docket says what it says. You're not paying for insight. You're paying for someone else's reading of the same primary sources — with their biases baked in.
Drug markets move fast. A competitor files an ANDA. A court issues an injunction. A biosimilar gets the nod. These things happen on a Tuesday.
Your quarterly report arrives on a Thursday — three months later. You've already missed the window. The early-mover advantage went to whoever was watching the primary data in real time. Not waiting for someone to write it up nicely.
Here's the part nobody talks about. You get the conclusion. You don't get the spreadsheet.
You can't check their working. You can't run your own cut. You can't take it with you when the contract ends. The data is theirs. The methodology is theirs. If you want to ask a different question than the one they answered, that's a new engagement — new invoice, new wait.
DrugPatentWatch pulls directly from primary sources — the USPTO, FDA Orange Book, ANDA filings, litigation records, patent registers across 134 countries. Every source an analyst would use. Updated daily. No middleman.
You form your own view. You run your own queries. You export everything and it's yours — permanently. When the contract ends, the data doesn't disappear.
Found the results very comprehensive. The information told me who potential competitors are and what they are planning based on not only their NDAs and patents, but also references to clinical trials.
Knowing when drugs are coming off patent and who to contract with has enabled us to stay ahead of the curve and align ourselves with the proper vendors.
An excellent opportunity for LATAM companies to access information on expired and protected patents from the USA and worldwide in a friendly and easy manner.
From US generics manufacturers to European biotech firms to LATAM distributors — DrugPatentWatch powers critical decisions across the global pharmaceutical industry.
Join thousands of pharmaceutical professionals who rely on DrugPatentWatch for authoritative, primary-source intelligence — updated every single day.